Physician

Kamal Eldin Mohamed Ahmed, M.D.

According to 2025 Medicare claims, Kamal Ahmed, M.D. (NPI: 1952352411) practices nephrology in the Yuma, AZ market, with the plurality of this provider's patient population coming from Yuma, AZ. This provider's primary affiliated billing organization is YUMA NEPHROLOGY PC (NPI: 1235185729; TIN: 860820509) and primary practice location at 85364-9998.

Ahmed's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 572 traditional Medicare patients, billed 10,679 HCPCS/CPT codes, and received $244,753 in Medicare payments. The top billing code was 80069 (Kidney function blood test panel). Part D data shows 2,699 prescription claims across 431 beneficiaries totaling $394,464 in drug costs, led by Sevelamer Hcl (Sevelamer Hcl). DME data shows 370 claims. Open Payments data shows 21 records totaling $415. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $380,897 to $244,753. Similarly, Part D prescription costs started with an early spike, then settled into a lower baseline, moving from $1,084,652 to $394,464. In contrast, DME billing represents a smaller volume and changed little.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	737	34,385	$380,897
2016	785	25,572	$377,538
2017	812	31,270	$356,830
2018	780	48,378	$329,567
2019	1,016	48,807	$404,913
2020	761	23,712	$359,716
2021	515	23,288	$230,170
2022	402	12,102	$185,207
2023	512	8,743	$263,645
2024	572	10,679	$244,753

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	476	4,976	$1,084,652
2016	470	5,829	$1,632,731
2017	452	5,264	$1,527,117
2018	443	4,020	$519,806
2019	424	3,393	$392,940
2020	389	2,973	$411,223
2021	354	2,720	$262,478
2022	349	2,462	$318,108
2023	396	2,455	$335,289
2024	431	2,699	$394,464

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	370	$22,810
2016	N/R	298	$15,062
2017	39	319	$14,120
2018	77	587	$32,574
2019	86	678	$22,987
2020	35	362	$11,460
2021	N/R	187	$5,774
2022	N/R	291	$6,206
2023	22	400	$7,211
2024	49	370	$6,485

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
80069	Kidney function blood test panel	240	399	$8
36415	Insertion of needle into vein for collection of blood sample	297	652	$8
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	249	485	$8
82570	Creatinine level to test for kidney function or muscle injury	238	374	$5
81001	Manual urinalysis test with examination using microscope, automated	237	382	$3

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Sevelamer Hcl	Sevelamer Hcl	36	3,060	$67,187
Sevelamer Carbonate	Sevelamer Carbonate	199	10,020	$63,558
Velphoro	Sucroferric Oxyhydroxide	23	1,170	$59,184
Lokelma	Sodium Zirconium Cyclosilicate	70	3,552	$51,770
Calcium Acetate	Calcium Acetate	268	14,984	$30,554

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7507	Tacrolimus, immediate release, oral, 1 mg	N	14	99	$1,958
J7517	Mycophenolate mofetil, oral, 250 mg	N	11	89	$1,714
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	13	103	$1,409
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	11	79	$1,404

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	21	$415	Outset Medical Inc
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Kamal Eldin Mohamed Ahmed, M.D.?

Tedicare shows public-source Medicare data for Kamal Eldin Mohamed Ahmed, M.D. (NPI 1952352411), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Kamal Eldin Mohamed Ahmed, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Kamal Eldin Mohamed Ahmed, M.D.?

Kamal Eldin Mohamed Ahmed, M.D. is linked to YUMA NEPHROLOGY PC (billing NPI 1235185729) in the available physician profile data.

Does Kamal Eldin Mohamed Ahmed, M.D. have Open Payments data?

Kamal Eldin Mohamed Ahmed, M.D. has 21 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.